Updating the Role of Natriuretic Peptide Levels in Cardiovascular Disease

References

• . Roger VL, Go AS, Lloyd-Jones DM, . American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2011 update: A report from the American Heart Association. Circulation. 2011; 123(4):e18–e209
   PubMed Web of Science ®Google Scholar
• . Remes J, Miettinen H, Reunanen A, Pyörälä K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J. 1991; 12(3):315
   PubMedGoogle Scholar
• . Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocrine Rev. 2006; 27(1):47
   PubMed Web of Science ®Google Scholar
• . Taub PR, Gabbai-Saldate P, Maisel A. Biomarkers of heart failure. Congest Heart Fail. 2010; 16( suppl 1):S19–S24
   Google Scholar
• . Maisel A, Koon J, Krishnaswamy P. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001; 141(3):367–374
   PubMed Web of Science ®Google Scholar
• . Novo G, Amoroso GR, Fazio G, Sutera F, Novo S. Biomarkers in heart failure. Front Biosci. 2009; 14:2484–2493
   Google Scholar
• . Cowie MR, Jourdain P, Maisel A, . Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J. 2003; 24(19):1710
   PubMed Web of Science ®Google Scholar
• . McCullough PA, Nowak RM, McCord J, . B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from breathing not properly (BNP) multinational study. Circulation. 2002; 106(4):416–422
   PubMed Web of Science ®Google Scholar
• . Maisel A, Krishnaswamy P, Nowak RM, . Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002; 347(3):161–167
   PubMed Web of Science ®Google Scholar
• . Januzzi JL Jr, Camargo CA, Anwaruddin S, . The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005; 95(8):948–954
   PubMed Web of Science ®Google Scholar
• . Baggish AL, van Kimmenade R, Bayes-Genis A, . Hemoglobin and N-terminal pro-brain natriuretic peptide: independent and synergistic predictors of mortality in patients with acute heart failure: Results from the international collaborative of NT-proBNP (ICON) study. Clinica Chimica Acta. 2007; 381(2):145–150
   PubMedGoogle Scholar
• . Mueller C, Scholer A, Laule-Kilian K, . Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004; 350(7):647–654
   PubMed Web of Science ®Google Scholar
• . Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA. 2005; 294(15):1944
   PubMed Web of Science ®Google Scholar
• . Maisel A, Hollander JE, Guss D, . Primary results of the rapid emergency department heart failure outpatient trial (REDHOT): A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004; 44(6):1328–1333
   PubMed Web of Science ®Google Scholar
• . Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006; 92(6):843–849
   PubMed Web of Science ®Google Scholar
• . Cheng V, Kazanagra R, Garcia A. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted with decompensated heart failure. J Am Coll Cardiol. 2001; 37(2):386–391
   PubMed Web of Science ®Google Scholar
• . Logeart D, Thabut G, Jourdain P, . Predischarge B-type natriuretic peptide assay for identifying patients at high risk of readmission after decompensated heart failure. J Am Coll Cardiol. 2004; 43(4):635–641
   PubMed Web of Science ®Google Scholar
• . Verdiani V, Nozzoli C, Bacci F, . Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. Eur J Heart Fail. 2005; 7(4): 566–571
   PubMed Web of Science ®Google Scholar
• . Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure. Can Med Assoc J. 2006; 175(6): 611–617
   Google Scholar
• . Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic review. BMJ. 2005; 330(7492):625
   PubMed Web of Science ®Google Scholar
• . Noveanu M, Breidthardt T, Potocki M, . Direct comparison of serial B-type natriuretic peptide and NT-proBNP levels for prediction of short-and long-term outcome in acute decompensated heart failure. Crit Care. 2011; 15(1):R1
   Google Scholar
• . Zugck C, Haunstetter A, Krüger C, . Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol. 2002; 39(10):1615–1622
   PubMedGoogle Scholar
• . Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. Eur Heart J. 2003; 24(19):1735–1743
   PubMed Web of Science ®Google Scholar
• . Bayés-Genís A, Santaló-Bel M, Zapico-Muñiz E, . N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail. 2004; 6(3):301–308
   PubMedGoogle Scholar
• . Di Somma S, Magrini L, Mazzone M, . Decrease in NTproBNP plasma levels indicates clinical improvement of acute decompensated heart failure. Am J Emerg Med. 2007; 25(3):335–339
   PubMed Web of Science ®Google Scholar
• . Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004; 110(15):2168–2174
   PubMed Web of Science ®Google Scholar
• . Di Somma S, Magrini L, Pittoni V, . In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: The Italian RED study. Crit Care. 2010; 14(3):R116
   PubMedGoogle Scholar
• . Bayés-Genís A, Lopez L, Zapico E, . NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. J Card Fail. 2005; 11( 5 suppl):S3–S8
   PubMed Web of Science ®Google Scholar
• . Bettencourt P, Januzzi JL Jr. Amino-terminal pro-B-type natriuretic peptide testing for inpatient monitoring and treatment guidance of acute destabilized heart failure. Am J Cardiol. 2008; 101(3):S67–S71
   PubMedGoogle Scholar
• . Parissis JT, Nikolaou M, Birmpa D, . Clinical and prognostic value of duke's activity status index along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2009; 103(1):73–75
   PubMedGoogle Scholar
• . Parissis JT, Nikolaou M, Farmakis D, . Clinical and prognostic implications of self-rating depression scales and plasma B-type natriuretic peptide in hospitalised patients with chronic heart failure. Heart. 2008; 94(5):585–589
   PubMedGoogle Scholar
• . Herrmann-Lingen C, Binder L, Klinge M, . High plasma levels of N-terminal pro-atrial natriuretic peptide associated with low anxiety in severe heart failure. Psychosom Medicine. 2003; 65(4):517–522
   PubMedGoogle Scholar
• . Hjalmarson A, Goldstein S, Fagerberg B, . Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA. 2000; 283(10): 1295–1302
   PubMed Web of Science ®Google Scholar
• . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet. 1999; 353(9146):9–13
   PubMed Web of Science ®Google Scholar
• . Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol. 1988; 62(2): 60A–66A
   PubMed Web of Science ®Google Scholar
• . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991; 325(5):293–302
   PubMedGoogle Scholar
• . Pitt B, Zannad F, Remme WJ, . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10):709–717
   PubMed Web of Science ®Google Scholar
• . Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H, Nicholls MG. Brain natriuretic factor: Regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J. 1993; 69(5):414
   PubMedGoogle Scholar
• . Haug C, Metzele A, Kochs M, Hombach V, Grünert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol. 1993; 16(7):553–557
   PubMedGoogle Scholar
• . Morita E, Yasue H, Yoshimura M, . Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 1993; 88(1):82–91
   PubMedGoogle Scholar
• . Yoshimura M, Yasue H, Okumura K, . Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993; 87(2): 464–469
   PubMed Web of Science ®Google Scholar
• . Tsutamoto T, Wada A, Maeda K, . Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001; 37(5): 1228–1233
   PubMedGoogle Scholar
• . McKelvie RS, Yusuf S, Pericak D, . Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999; 100(10):1056–1064
   PubMed Web of Science ®Google Scholar
• . Anand IS, Fisher LD, Chiang YT, . Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003; 107(9): 1278–1283
   PubMed Web of Science ®Google Scholar
• . Troughton RW, Frampton CM, Yandle TG, . Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000; 355(9210):1126–1130
   PubMed Web of Science ®Google Scholar
• . Jourdain P, Jondeau G, Funck F, . Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP multicenter study. J Am Coll Cardiol. 2007; 49(16): 1733–1739
   PubMed Web of Science ®Google Scholar
• . Lainchbury JG, Troughton RW, Strangman KM, . N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: Results from the BATTLESCARRED (NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009; 55(1):53–60
   PubMed Web of Science ®Google Scholar
• . Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med. 2010; 170(6):507–514
   PubMedGoogle Scholar
• . Bhardwaj A, Rehman SU, Mohammed A, Baggish AL, Moore SA, Januzzi JL Jr. Design and methods of the pro-B type natriuretic peptide outpatient tailored chronic heart failure therapy (PROTECT) study. Am Heart J. 2010; 159(4):532–538.e1
   PubMed Web of Science ®Google Scholar
• . Shah MR. STARBRITE: A randomized pilot trial of BNP-guided therapy in patients with advanced heart failure. Circulation. 2006; 114( 18 suppl):II_528
   Google Scholar
• . Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlström U. Improved pharmacological therapy of chronic heart failure in primary care: A randomized Study of NT-proBNP Guided Management of Heart Failure—SIGNAL-HF (Swedish Intervention study—Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail. 2010; 12(12):1300–1308
   PubMed Web of Science ®Google Scholar
• . Pfisterer M, Buser P, Rickli H, . BNP-guided vs symptom-guided heart failure therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009; 301(4):383–392
   PubMed Web of Science ®Google Scholar
• . Cowie MR, Struthers AD, Wood DA. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997; 350(9088):1349–1353
   PubMed Web of Science ®Google Scholar
• . Wright SP, Doughty RN, Pearl A. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: A randomized, controlled trial. J Am Coll Cardiol. 2003; 42(10):1793–1800
   PubMedGoogle Scholar
• . Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction. Circulation. 2004; 109(25): 3176–3181
   PubMed Web of Science ®Google Scholar
• . Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004; 110(20):3206–3212
   PubMed Web of Science ®Google Scholar
• . Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002; 40(3):437–445
   PubMedGoogle Scholar
• . Richards AM, Nicholls MG, Espiner EA, . B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003; 107(22):2786–2792
   PubMed Web of Science ®Google Scholar
• . Gerber IL, Stewart RA, Legget ME. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation. 2003; 107(14):1884–1890
   PubMed Web of Science ®Google Scholar
• . Weber M, Arnold R, Rau M, . Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J. 2005; 26(10):1023
   PubMed Web of Science ®Google Scholar
• . Bergler-Klein J, Klaar U, Heger M. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation. 2004; 109(19):2302
   PubMed Web of Science ®Google Scholar
• . Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med. 2002; 3( suppl 4):S10–S17
   Google Scholar